TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

TransThera Sciences (Nanjing), Inc. (HKG: 2617) and Allist Pharmaceuticals Co., Ltd. (SHA: 688578) have announced a strategic partnership to jointly advance a multicenter, open-label Phase II clinical study evaluating the combination of TT-00973-MS and furmonertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations.

Partnership Framework

Investigational Combination Therapy

TT-00973 – TransThera’s Novel Dual-Target Inhibitor

• Molecule Type: Novel AXL/FLT3 dual-target inhibitor
• Development Status: In-house developed by TransThera Sciences
• Mechanism Rationale: AXL inhibition may overcome resistance mechanisms to EGFR-TKIs in NSCLC
• Therapeutic Innovation: Dual targeting addresses both primary driver (EGFR) and resistance pathways (AXL)

Furmonertinib – Allist’s Approved EGFR-TKI

• Molecule Type: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)
• Development Status: Developed and commercialized by Allist Pharmaceuticals
• Current Indications: Approved for EGFR-mutant NSCLC in China
• Combination Rationale: Established efficacy as monotherapy provides foundation for enhanced combination approach

Clinical Study Design

• Phase: Phase II (multicenter, open-label)
• Patient Population: Locally advanced or metastatic NSCLC with EGFR-sensitive mutations
• Primary Endpoints: Safety and efficacy assessment of combination therapy
• Study Scope: Multiple clinical sites across China
• Future Pathway: Positive results to inform Phase III trial design and potential regulatory submissions

Strategic Rationale & Scientific Basis

Overcoming EGFR-TKI Resistance

• Clinical Challenge: Acquired resistance to EGFR-TKIs remains major limitation in NSCLC treatment
• AXL Pathway Role: AXL activation identified as key resistance mechanism to EGFR inhibition
• Dual-Target Approach: Simultaneous inhibition of EGFR and AXL may delay or prevent resistance development
• FLT3 Component: Additional FLT3 inhibition may provide broader anti-tumor activity

Commercial Synergies

• Complementary Portfolios: Combines TransThera’s novel targeted therapy with Allist’s established EGFR-TKI
• Market Expansion: Potential to extend furmonertinib’s lifecycle through combination indication
• Risk Sharing: Efficient resource allocation with TransThera funding operations and Allist providing drug supply
• Regulatory Strategy: Leverages existing furmonertinib approval while developing novel combination regimen

Market Context & Competitive Landscape

• EGFR-Mutant NSCLC Market: $8+ billion global market with significant growth in Asia-Pacific region
• China Leadership: Both companies represent leading Chinese oncology innovators with domestic regulatory expertise
• Combination Therapy Trend: Industry shift toward rational combinations to address resistance mechanisms
• Competitive Positioning: Differentiates from other EGFR-TKI combinations through novel AXL/FLT3 dual inhibition

Development Timeline & Next Steps

• Current Status: Phase II study initiation underway
• Data Readouts: Expected 2027-2028 timeframe
• Phase III Planning: Joint evaluation of Phase II results to determine Phase III trial feasibility
• Partnership Evolution: Framework established for potential expanded collaboration beyond initial study

Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, partnership outcomes, and market expectations for the TT-00973/furmonertinib combination. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and partnership execution challenges.-Fineline Info & Tech